“Biologics”, which selectively target the type 2 inflammatory cascade by binding to specific interleukins such as IL-4, IL-5, and IL-13 or their respective receptors, is a reliable treatment option for all those CRSwNP patients who experience failure of conventional therapy during follow-up [5,34]. The gene discussed is IL5; the disease is chronic rhinosinusitis with nasal polyps.